Navigation Links
Neurocrine Biosciences Amends Corporate Headquarters Lease
Date:10/1/2009

SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company has entered into an amendment to its facility lease agreement. The amendment eliminates approximately 70,000 square feet of leased space.

"We worked with our landlord in a collaborative manner to reduce our leasing obligation and to allow them to directly market the property, while at the same time minimizing the cash flow impact to Neurocrine," said Timothy P. Coughlin, Vice President and Chief Financial Officer of Neurocrine Biosciences. "This is a significant first step in reducing our fixed real estate cost structure, reducing our overall obligation by approximately $27 million."

Under the terms of the lease amendment, Neurocrine will vacate the front building of the two building campus and will make an immediate payment of $4 million to the landlord as an initial release fee. Additionally, the Company has agreed to make certain rent payments and rent differential payments with respect to the released space.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

SOURCE Neurocrine Biosciences, Inc.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
2. Neurocrine Biosciences Secures Committed Equity Financing Facility
3. Neurocrine Biosciences Reports Second Quarter 2009 Results
4. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
6. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
7. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
8. Neurocrine Biosciences Reports First Quarter 2009 Results
9. Neurocrine Announces Work Force Restructuring
10. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
11. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... CAMBRIDGE, Mass. , Feb. 27, 2015 /PRNewswire-USNewswire/ ... Analysis of the NCATS rare-diseases portfolio " in ... of a new financing technique to reduce the ... new diseases and potentially unlock new levels of ... The product of a unique collaboration between ...
(Date:2/27/2015)... DIEGO , Feb. 27, 2015  Pfenex Inc. ... the development of biosimilar therapeutics, today announced that it ... Francisco Marriott Marquis on March 2 nd at ... participate on a panel discussing the current state of ... of Biosimilars . For more information ...
(Date:2/26/2015)... S&P Capital IQ (MHFI) announced today that ... MabVax Therapeutics Holdings Inc . MabVax ... company focused on the development of vaccine and antibody-based ... of cancer. MabVax has discovered a pipeline of human ... generated by patients who have been immunized against targeted ...
(Date:2/26/2015)... 2015   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... Chief Executive Officer of Regulus, will present a company ... Annual Healthcare Conference on Wednesday, March 4, 2015 at ... the Boston Marriott Copley Place.  The ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... NEW YORK, May 7 When leading contract research,organization ... system to a voice-over Internet protocol (VoIP),system that would ... nothing short of catastrophic., POI initially selected a ... but it was immediately clear the solution was a ...
... Carbon nanotubes potential as a super material is blighted ... take the form of an unprepossessing pile of sooty black ... in the University of Warwicks Department of Chemistry have found ... form a highly sensitive ready made electric circuit. , The ...
... Leading Venture Contest Makes Carnegie Mellon ,Winningest, ... ... team of,students from the Tepper School of Business at Carnegie Mellon have ... This year,s winning venture business -- NeuroBank -- has developed,a breakthrough proprietary ...
Cached Biology Technology:Pharm-Olam Finds VoIP Solution in Taridium LLC 2Nanotube production leaps from sooty mess in test tube to ready formed chemical microsensors 2Tepper School Team Takes Top Honors at Global Moot Corp(R) Competition 2
(Date:1/22/2015)... 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased ... State of Washington,s Department of Licensing, ... and central issuance system for driver,s licenses and identification cards ... planning and development will start in January 2015, with enrollment ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... hybrid laboratory antibodies derived from chimpanzees and humans may ... the serious complications that can occur following smallpox vaccination--and ... The study, led by researchers with the National Institute ... National Institutes of Health (NIH), appears online this week ...
... the McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins ... analyzing what many have termed "junk" DNA and identified ... found that these control regions from different species don't ... study will be published online at Science Express March ...
... state-of-the-art anti-aging technologies may extend human lifespans at an ... and economic challenges, says biologist Shripad Tuljapurkar of Stanford ... would have major implications for the global community in ... Professor of Population Studies, will give a talk Feb. ...
Cached Biology News:Mice studies illustrate potential of chimp/human antibodies to protect against smallpox 2Mice studies illustrate potential of chimp/human antibodies to protect against smallpox 3Junk DNA may not be so junky after all 2Junk DNA may not be so junky after all 3World faces challenge as life expectancies lengthen, scientist says 2World faces challenge as life expectancies lengthen, scientist says 3World faces challenge as life expectancies lengthen, scientist says 4
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Tube-O-DIALYZER Floats, small....
Biology Products: